GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Panacos Pharmaceuticals, Inc. (PANC) [hlAlert]

Rating:
Buy PANC
down 99.94 %

Panacos Pharmaceuticals, Inc. (PANC) rated Buy

Posted on: Tuesday,  Dec 11, 2007  1:25 PM ET by Deutsche Securities

Deutsche Securities rated Buy Panacos Pharmaceuticals, Inc. (OTCBB: PANC) on 12/11/2007, when the stock price was $0.97. Since
then, Panacos Pharmaceuticals, Inc. has lost 99.95% as of 08/07/2015's recent price of $0.00.
If you would have followed this Deutsche Securities's recommendation on PANC, you would have lost 99.94% of your investment in 2796 days.

Panacos Pharmaceuticals, Inc. (Panacos) is a development-stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.

Deutsche Bank's award-winning Research team manages a range of functions from asset allocation, through economic forecasting across a broad range of industry sectors including cement and construction, chemicals, electronics, energy, engineering, machinery, media, software, tobacco, retailing and utilities, and oil and gas.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/11/2007 1:25 PM Buy
None
0.97 3.00
as of 8/27/2015
1 Week   
1 Month up  400.00 %
3 Months up  400.00 %
1 YTD down  -80.76 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy